Beta-blockers have long been considered a cornerstone of therapy for patients with acute myocardial infarction (MI).
Resistant hypertension, defined as a systolic blood pressure (BP) that remains above goal despite treatment with at least three complementary antihypertensive agents of different classes at maximally tolerated doses, has become an increasingly common diagnosis in recent years.
Coronary artery stents are implanted in the vast majority of coronary revascularization procedures, owing to improvements in both restenosis and acute vessel occlusion vs balloon angioplasty alone.
The cause of ischemic stroke remains uncertain despite a complete diagnostic evaluation in many cases. Detection of atrial fibrillation (AF) after cryptogenic stroke would have important therapeutic implications.
The clinical implications of the recovery of left ventricular (LV) function after treatment of patients with initial systolic heart failure is poorly understood.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and has been the leading arrhythmic cause for hospitalization.
